Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Other

Another Inclisiran CVOT (VICTORION-2P); Not Even in Primary Prevention

Here is a brief preview of this blast: A CT.gov record has been observed for another Ph3 inclisiran CVOT, called VICTORION-2 PREVENT (aka VICTORION-2P), in 15,000 adults 40 years of age and older with established ASCVD (view CT.gov record). Notably, the VICTORION-2P trial is evaluating inclisiran in secondary prevention, which is similar to ORION-4 (ongoing with primary completion in 2026; view CT.gov record). Below, FENIX provides additional trial details as well as thoughts on the trial design in comparison to ORION-4.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.